| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8178518 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7608608 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7608610 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US8063029 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7608605 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7608607 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7608609 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7935690 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7608606 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(5 months ago) | |
| US7320968 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Jan, 2025
(1 year, 3 months from now) | |
Testim is owned by Auxilium Pharms Llc.
Testim contains Testosterone.
Testim has a total of 10 drug patents out of which 9 drug patents have expired.
Expired drug patents of Testim are:
- US8178518
- US7608608
- US7608610
- US8063029
- US7608605
- US7608607
- US7608609
- US7935690
- US7608606
Testim was authorised for market use on 31 October, 2002.
Testim is available in gel;transdermal dosage forms.
Testim can be used as method for administration of testosterone.
The generics of Testim are possible to be released after 18 January, 2025.
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 31 October, 2002
Treatment: Method for administration of testosterone
Dosage: GEL;TRANSDERMAL
TESTIM family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic